Amesite's fiscal third quarter delivered a story that almost writes itself, and almost reads itself. Net revenue of $83,332 in the three months ended March 31, 2026 was up roughly 2.7x from a year-ago $30,690; for the nine months it was $285,678, up more than 5x from $54,700, driven almost entirely by a single B2B contract ramp. Net loss for the quarter held essentially flat at $678,061 versus $663,418 a year earlier, and for the nine months narrowed to $2.05M from $2.69M. Cash used in operations fell to $1.49M from $2.02M - a 26% reduction that, on an annualized basis, runs a touch under $2M. The picture is of a single-segment, pre-profitability software company whose top line is no longer rounding to zero and whose burn is no longer the whole story.
There are two ways to read the rest of the report, and the quarter obliges the report to print both. The first reading is the obvious one: revenue accelerating, loss shrinking, a 2,700-patient enterprise customer announced May 18 as the platform's "largest deployment to date." The second is the one management's own going-concern footnote forces. Amesite ended the quarter with $740,711 of cash and restricted cash, and the auditor-signed statement explicitly says management's plans - to fund operations through additional equity offerings - "do not alleviate substantial doubt about the Company's ability to continue as a going concern." A $2.2M net April 28 offering bought the company compliance with Nasdaq's $2.5M minimum stockholders' equity rule; it did not buy the company solvency. The May 18 deal lifts revenue but not cash; a new ATM facility on July 17 widened the runway but not the visibility. The result is a quarter that, for the first time, looks like a software business - and a balance sheet that, for the foreseeable future, looks like a start-up.
The company is small enough that market mechanics matter more than operating story. With $6.5M of common shares outstanding (basic + pre-funded warrants treated as exercised) at a reference price of $1.03 on August 12, market capitalization is roughly $6.7M. Against an estimated $2.9M of cash after the April raise, enterprise value is roughly $3.8M. Trailing-twelve-month revenue of about $341,000 puts the stock at roughly 20x P/S and 11x EV/S - a multiple that prices a successful enterprise pivot, not a struggling one. The 52-week high of $3.87 (September 11, 2025) and low of $0.77 (May 18, 2026) bracket a year in which the stock has spent most of its time below $1.50 while the company changed its address, changed its product, and changed what kind of business it is. The thesis is unproven, the runway is short, and the dilution is structural. The thesis can still win.